https://www.globenewswire.com/news-release/2022/12/21/2577734/0/en/BioNTech-Starts-Phase-1-Clinical-Trial-for-Prophylactic-Herpes-Simplex-Virus-2-Vaccine-Candidate-BNT163.html
0
0
12/21/22 at 11:45am
Organization
GlobeNewswire
Author
BioNTech SE
39 words
0
Comments
First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate......
You are the first to view
Create an account
or login to join the discussion